Company

Haemonetics Corporation

Headquarters: Boston, MA, United States

Founded: 1971

Employees: 2,708

CEO: Mr. Christopher A. Simon

NYSE: HAE -1.67%

Market Cap

$4.13 Billion

USD as of Jan. 1, 2024

Market Cap History

Haemonetics Corporation market capitalization over time

Evolution of Haemonetics Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Haemonetics Corporation

Detailed Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Haemonetics Corporation has the following listings and related stock indices.


Stock: NYSE: HAE wb_incandescent

Stock: FSX: HAZ wb_incandescent

Key People

Christopher Simon, CEO, President Michelle L. Basil, E VP, General Counsel William P. Burke, E VP, Chief Financial Officer David Gueundjian, President, International Carter Houghton, President, Hospital Chad Nikel, VP, Global Blood Center Kevin O' Kelly- Lynch, SVP, Global Business Services Ian Purdy, Ph D, SVP, Global Quality and Regulatory Affairs Neil Ryding, E VP, Global Operations Jacqueline Scanlan, SVP, Human Resources Francis Tan, SVP, Corporate Development and Planning David J. Wilson, President, Global Plasma

Financials

Revenue: $988 Million(2020)

Details

Headquarters:

125 Summer Street

Boston, MA 02110

United States

Phone: 781 848 7100